Myotoxicity of telbivudine in pre-existing muscle damage
<p>Abstract</p> <p>Objectives</p> <p>It is unknown if telbivudine causes muscle damage only in patients with pre-existing muscle pathology.</p> <p>Case report</p> <p>A 27 yo male of African origin received telbivudine for hepatitis B during 3 mon...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-11-01
|
Series: | Virology Journal |
Online Access: | http://www.virologyj.com/content/7/1/323 |
id |
doaj-6d902e0da23742fd89686c5e9d7c0e2a |
---|---|
record_format |
Article |
spelling |
doaj-6d902e0da23742fd89686c5e9d7c0e2a2020-11-25T02:19:06ZengBMCVirology Journal1743-422X2010-11-017132310.1186/1743-422X-7-323Myotoxicity of telbivudine in pre-existing muscle damageAy LeylaFinsterer Josef<p>Abstract</p> <p>Objectives</p> <p>It is unknown if telbivudine causes muscle damage only in patients with pre-existing muscle pathology.</p> <p>Case report</p> <p>A 27 yo male of African origin received telbivudine for hepatitis B during 3 months. Three weeks after initiation of the drug he developed myalgia, and tiredness. Creatine-kinase increased from 278 U/l (n, <170 U/l) at baseline to 3243 U/l. Shortly after discontinuation of telbivudine muscle symptoms and hyper-CK-emia disappeared. The findings suggest that pre-existing muscle damage favored the myotoxic effect of telbivudine.</p> <p>Conclusions</p> <p>Telbivudine appears to cause accelerated muscle toxicity if given to patients who already have muscle damage. Patients under telbivudine should be closely monitored for muscular side effects and those with pre-existing muscle damage should not receive the drug.</p> http://www.virologyj.com/content/7/1/323 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ay Leyla Finsterer Josef |
spellingShingle |
Ay Leyla Finsterer Josef Myotoxicity of telbivudine in pre-existing muscle damage Virology Journal |
author_facet |
Ay Leyla Finsterer Josef |
author_sort |
Ay Leyla |
title |
Myotoxicity of telbivudine in pre-existing muscle damage |
title_short |
Myotoxicity of telbivudine in pre-existing muscle damage |
title_full |
Myotoxicity of telbivudine in pre-existing muscle damage |
title_fullStr |
Myotoxicity of telbivudine in pre-existing muscle damage |
title_full_unstemmed |
Myotoxicity of telbivudine in pre-existing muscle damage |
title_sort |
myotoxicity of telbivudine in pre-existing muscle damage |
publisher |
BMC |
series |
Virology Journal |
issn |
1743-422X |
publishDate |
2010-11-01 |
description |
<p>Abstract</p> <p>Objectives</p> <p>It is unknown if telbivudine causes muscle damage only in patients with pre-existing muscle pathology.</p> <p>Case report</p> <p>A 27 yo male of African origin received telbivudine for hepatitis B during 3 months. Three weeks after initiation of the drug he developed myalgia, and tiredness. Creatine-kinase increased from 278 U/l (n, <170 U/l) at baseline to 3243 U/l. Shortly after discontinuation of telbivudine muscle symptoms and hyper-CK-emia disappeared. The findings suggest that pre-existing muscle damage favored the myotoxic effect of telbivudine.</p> <p>Conclusions</p> <p>Telbivudine appears to cause accelerated muscle toxicity if given to patients who already have muscle damage. Patients under telbivudine should be closely monitored for muscular side effects and those with pre-existing muscle damage should not receive the drug.</p> |
url |
http://www.virologyj.com/content/7/1/323 |
work_keys_str_mv |
AT ayleyla myotoxicityoftelbivudineinpreexistingmuscledamage AT finstererjosef myotoxicityoftelbivudineinpreexistingmuscledamage |
_version_ |
1724878471460552704 |